Cargando…

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India

Introduction  Multiple myeloma (MM) forms a significant proportion of hematological malignancies. Autologous transplantation continues to be an effective consolidation strategy in resource-restricted settings such as India. Objectives  The main objective of the study was to analyze the clinical outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sood, Nitin, Tiwari, Aseem Kumar, Pabbi, Swati, Dikshit, Roshan, Singh, Prerna, Ramaswami, Amrita, Gautam, Dheeraj, Singh, Manish Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635772/
https://www.ncbi.nlm.nih.gov/pubmed/37969670
http://dx.doi.org/10.1055/s-0042-1748184
_version_ 1785146360535711744
author Sood, Nitin
Tiwari, Aseem Kumar
Pabbi, Swati
Dikshit, Roshan
Singh, Prerna
Ramaswami, Amrita
Gautam, Dheeraj
Singh, Manish Kumar
author_facet Sood, Nitin
Tiwari, Aseem Kumar
Pabbi, Swati
Dikshit, Roshan
Singh, Prerna
Ramaswami, Amrita
Gautam, Dheeraj
Singh, Manish Kumar
author_sort Sood, Nitin
collection PubMed
description Introduction  Multiple myeloma (MM) forms a significant proportion of hematological malignancies. Autologous transplantation continues to be an effective consolidation strategy in resource-restricted settings such as India. Objectives  The main objective of the study was to analyze the clinical outcomes of autologous hematopoietic stem cell transplant (HSCT) in MM patients in a single tertiary care center in north India over a period of 5 years. Materials and Methods  This retrospective observational study was conducted in a tertiary care center in north India. Data of all MM patients who underwent HSCT between January 2014, and December 2018, were analyzed. The outcome of HSCT was investigated in terms of transplant-related mortality (TRM), progression-free survival (PFS), overall survival (OS), and relapse. PFS and OS were calculated by Kaplan–Meier method and differences between the groups were tested for statistical significance using the two-tailed log-rank test. Life-table method was used for the estimation of survival rate at 1, 3, 5, and 6 years. Results  Patient characteristics and survival post-transplant was similar to other published Indian studies. In total, 378 patients were diagnosed with MM in our hospital between 2014 and 2018. One hundred ninety-three patients were found to be eligible for autologous HSCT, out of which 52 ended up having a transplant giving us a high percentage (26.9%) of patients receiving a transplant in our setting. Transplant-related mortality (TRM) was nil in the present study. The mean PFS and OS were 62.8 and 70.1 months, respectively. The mean PFS and OS rates at 5 years were 75.3% and 84.2%, respectively. The average cost estimate of HSCT in our setting was 7.2 lakh Indian national rupees. Conclusion  Autologous HSCT is a safe procedure with nil 100-day mortality in present series. Moreover, considering the cost of novel agents, autologous transplant remains a cost-effective way for prolonging remission and time-to-next treatment in India.
format Online
Article
Text
id pubmed-10635772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-106357722023-11-15 Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India Sood, Nitin Tiwari, Aseem Kumar Pabbi, Swati Dikshit, Roshan Singh, Prerna Ramaswami, Amrita Gautam, Dheeraj Singh, Manish Kumar South Asian J Cancer Introduction  Multiple myeloma (MM) forms a significant proportion of hematological malignancies. Autologous transplantation continues to be an effective consolidation strategy in resource-restricted settings such as India. Objectives  The main objective of the study was to analyze the clinical outcomes of autologous hematopoietic stem cell transplant (HSCT) in MM patients in a single tertiary care center in north India over a period of 5 years. Materials and Methods  This retrospective observational study was conducted in a tertiary care center in north India. Data of all MM patients who underwent HSCT between January 2014, and December 2018, were analyzed. The outcome of HSCT was investigated in terms of transplant-related mortality (TRM), progression-free survival (PFS), overall survival (OS), and relapse. PFS and OS were calculated by Kaplan–Meier method and differences between the groups were tested for statistical significance using the two-tailed log-rank test. Life-table method was used for the estimation of survival rate at 1, 3, 5, and 6 years. Results  Patient characteristics and survival post-transplant was similar to other published Indian studies. In total, 378 patients were diagnosed with MM in our hospital between 2014 and 2018. One hundred ninety-three patients were found to be eligible for autologous HSCT, out of which 52 ended up having a transplant giving us a high percentage (26.9%) of patients receiving a transplant in our setting. Transplant-related mortality (TRM) was nil in the present study. The mean PFS and OS were 62.8 and 70.1 months, respectively. The mean PFS and OS rates at 5 years were 75.3% and 84.2%, respectively. The average cost estimate of HSCT in our setting was 7.2 lakh Indian national rupees. Conclusion  Autologous HSCT is a safe procedure with nil 100-day mortality in present series. Moreover, considering the cost of novel agents, autologous transplant remains a cost-effective way for prolonging remission and time-to-next treatment in India. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-08-16 /pmc/articles/PMC10635772/ /pubmed/37969670 http://dx.doi.org/10.1055/s-0042-1748184 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Sood, Nitin
Tiwari, Aseem Kumar
Pabbi, Swati
Dikshit, Roshan
Singh, Prerna
Ramaswami, Amrita
Gautam, Dheeraj
Singh, Manish Kumar
Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
title Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
title_full Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
title_fullStr Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
title_full_unstemmed Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
title_short Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-year Experience from a Single Centre in North India
title_sort clinical outcomes of autologous hematopoietic stem cell transplant in multiple myeloma patients: a 5-year experience from a single centre in north india
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635772/
https://www.ncbi.nlm.nih.gov/pubmed/37969670
http://dx.doi.org/10.1055/s-0042-1748184
work_keys_str_mv AT soodnitin clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia
AT tiwariaseemkumar clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia
AT pabbiswati clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia
AT dikshitroshan clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia
AT singhprerna clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia
AT ramaswamiamrita clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia
AT gautamdheeraj clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia
AT singhmanishkumar clinicaloutcomesofautologoushematopoieticstemcelltransplantinmultiplemyelomapatientsa5yearexperiencefromasinglecentreinnorthindia